PLSE 8-K: SEC filing

Pulse Biosciences

Filed with the SEC on Nov 6, 2026 · accession 0001437749-26-035410

PLSE filed a 8-K (current report) with the SEC on Nov 6, 2026. Pulse Biosciences announced positive six-month interim results from its PRECISE-BTN multicenter study evaluating the nPulse Vybrance Percutaneous Electrode System for treating benign thyroid nodules, with 86% of patients achieving the primary endpoint of at least 50% nodule volume reduction and no…

Summary of the filing

Pulse Biosciences announced positive six-month interim results from its PRECISE-BTN multicenter study evaluating the nPulse Vybrance Percutaneous Electrode System for treating benign thyroid nodules, with 86% of patients achieving the primary endpoint of at least 50% nodule volume reduction and no serious adverse events.

For details, click here →How to read a 8-K →

Key details

IssuerPulse Biosciences, Inc.

Clinical trial siteSarasota Memorial Health Care System

Clinical trial siteNYU Langone Health

Clinical trial siteWeill Cornell Medicine

Principal investigator, precise-btn studyRalph Tufano

Ceo and co-chairman of pulse biosciencesPaul LaViolette

Investigator, weill cornell medicineThomas Fahey

Investigator, nyu langone healthKepal Patel

✦ Ask GOAX AI about this filing — what it means for PLSE, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PLSE?

Click here

Frequently asked questions

What did PLSE file with the SEC on Nov 6, 2026?

PLSE filed a 8-K (SEC filing). Pulse Biosciences announced positive six-month interim results from its PRECISE-BTN multicenter study evaluating the nPulse Vybrance Percutaneous Electrode System for treating benign thyroid nodules, with 86% of patients achieving the primary endpoint of at least 50% nodule volume reduction and no serious adverse events.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other PLSE SEC filings

Get alerts when PLSE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

PLSE overview PLSE analysis PLSE news Latest SEC filings